Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
  • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
  • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin

Definitions

• the present invention relates to photopolymerizable hydrogel materials that produce physiologically relevant amounts of nitric oxide (NO) for prolonged periods of time.
• NO nitric oxide
• Endothelial cells normally present as a monolayer in the intimal layer of the arterial wall, are believed to play an important role in the regulation of smooth muscle cell proliferation in vivo. Endothelial cells are seriously disrupted by most forms of vascular injury, including that caused by percutaneous transluminal coronary angioplasty and similar procedures. Approximately 35-50% of patients treated by percutaneous transluminal coronary angioplasty experience clinically significant renarrowing of the artery, or restenosis, within six months of the initial treatment. Restenosis is due, at least in part, to migration and proliferation of smooth muscle cells in the arterial wall along with increases in secretion of matrix proteins to form an obstructive neointimal layer within the arterial wall.
• NO is an endothelium-derived target molecule useful for the prevention of restenosis because, in addition to limiting the proliferation of smooth muscle cells (Garg et al., 1989), NO reduces platelet aggregation (de Graaf et al., 1992; Radomski et al., 1987), increases endothelial cell proliferation (Ziche et al., 1993), and attenuates leukocyte adhesion (Lefer et al., 1993), all of which are highly desirable for the reduction of intimal thickening and restenosis (Reviewed by Loscalzo, 1996). Because of the complexity of the restenotic process, approaches that act upon multiple targets are the most likely to be successful.
• NO cyclic guanosine monophosphate
• cGMP cyclic guanosine monophosphate
• the effects of NO can often be mimicked by the administration of cGMP or more stable derivatives of cGMP (Garg et al., 1989).
• NO has been found to inhibit ribonucleotide reductase, an enzyme that converts ribonucleotides into deoxy ribonucleotides, thus significantly impacting DNA synthesis (Lepoivre et al., 1991; Kwon et al., 1991), as well as several enzymes involved in cellular respiration (Stuehr et al., 1989).
• NO donor molecules A number of molecules that produce NO under physiological conditions (NO donors) have been identified and evaluated both in vitro and in vivo. NO donor molecules exert biological effects mimicking those of NO and include S-nitrosothiols (Diodati et al, 1993; Lefer et al., 1993; DeMeyer et al., 1995), organic nitrates (Ignarro et al., 1981), and complexes of NO with nucleophiles (Diodati et al., 1993; Diodati et al., 1993; Maragos et al., 1993).
• S-nitrosothiols Diodati et al, 1993; Lefer et al., 1993; DeMeyer et al., 1995
• organic nitrates Ignarro et al., 1981
• complexes of NO with nucleophiles Diodati et al., 1993; Diodat
• L-arginine is often thought of as a NO donor, as L-arginine is a substrate for NO synthase, and thus administration of L- arginine increases endogenous NO production and elicits responses similar to those caused by NO donors in most cases (Cooke et al., 1992).
• NO-releasing polymers containing NO/nucleophile complexes has been reported by Smith et al., (1996).
• These materials were capable of releasing NO for as long as 5 weeks in vitro and were able to limit smooth muscle cell proliferation in culture and to reduce platelet adherence to vascular graft materials in an arterio-venous shunt model. These materials show promise for numerous clinical applications where localized NO production would be desired, such as anti-thrombotic coating materials for catheters, but probably will not be useful for the direct treatment of tissues in vivo as these materials suffer from a number of disadvantages.
• These polymers may be produced as films, powders, or microspheres, but they cannot be formed in situ in direct contact with cells and tissues, thus making it difficult to strictly localize NO treatment to a tissue and potentially causing issues with the retention of the polymer at the site of application.
• Biocompatible polymeric materials releasing or producing NO are applied to sites on or in a patient in need of treatment thereof for disorders such as restenosis, thrombosis, asthma, wound healing, arthritis, penile erectile dysfunction or other conditions where NO plays a significant role.
• the polymeric materials can also be formed into films, coatings, or microparticles.
• the polymers are typically formed of macromers, which preferably include biodegradable regions, and have bound thereto groups that are released in situ to elevate or otherwise modulate NO levels at the site where treatment is needed.
• the macromers can form a homo or hetero- dispersion or solution, which is polymerized to form a polymeric material, that in the latter case can be a semi-interpenetrating network or interpenetrating network.
• Compounds to be released can be physically entrapped, covalently or ionically bound to macromer, or actually form a part of the polymeric material.
• Hydrogels can be formed by ionic and/or covalent crosslinking.
• Other active agents including therapeutic, prophylactic, or diagnostic agents, can also be included within the polymeric material.
• Figure 1 is a schematic of the synthesis of S-nitrosocysteine hydrogels (Acryloyl-PEG-CYSNO).
• Figure 2 is a schematic of the synthesis of acryloyl-PEG-Lysine NO- nucleophile complex hydrogels.
• Figure 3 is a schematic of the synthesis of acryloyl-PEG-DETA-NO- nucleophile complex hydrogels.
• Figure 4 is a graph showing the temporal release (%NO released over time in days) of NO from acryloyl-PEG-Lyss-NO hydrogels at pH 7.4
• Figure 5 is a graph showing the temporal release (%NO released over time in days) of NO from acryloyl-PEG-DETA-NO hydrogels at pH 7.4 (circles) and pH 2 (squares).
• Figure 6 is a graph showing the temporal release (%NO released over time in hours) of NO from PEG-CYSNO hydrogels at pH 7.4 (circles) and pH 2 (squares).
• Figure 7 is a graph showing the temporal release ( ⁇ mol NO released per gram of polymer over time in hours) of NO from PVA-NO-bFGF hydrogels at pH 7.4, 37°C.
• Figures 8A and 8B are graphs showing that acryloyl-PEG-Lysine-NO hydrogels inhibit the proliferation of smooth muscle cells.
• Figure 8 A % of control cell number, hydrogel formulation.
• Figure 8B % of control cell number, soluble polymer.
• Figures 9A and 9B are graphs showing the inhibition of SMC proliferation by NO released from acryloyl-PEG-DETA-NO hydrogels ( Figure 9A) and soluble polymer ( Figure 9B), as a percentage of the control.
• Figures 10A and 10B are graphs showing inhibition of SMC proliferation by NO released from acryloyl-PEG-CYSNO hydrogels ( Figure 10A) and soluble polymer ( Figure 10B), as a percentage of controls.
• Figure 11 is a graph comparing the degree of inhibition of smooth muscle cell growth by NO released from hydrogels: acryloyl-PEG-Lys-NO, acryloyl-PEG-DETA-NO, and acryloyl-PEG-CYSNO, compared to control hydrogel with NO.
• the %inhibition of smooth muscle cell growth is determined by comparing the cell growth for each NO-releasing hydrogel to a control PEG-diacrylate hydrogel.
• Figure 12a is a graph showing the temporal release of NO, micromolar NO released/gram of gel over time in hoursfrom PVA-NO-bFGF hydrogels at pH 7.4, 37°C.
• Figure 12b is a graph showing the temporal release (% of theoretical bFGF released per gram of gel over time in hours) from PVA-Cys-NO-bFGF hydrogels at pH 7.4, 37°C.
• the polymeric materials are biocompatible and release or produce NO.
• the polymers are also biodegradable, form hydrogels, polymerize in situ and are tissue adherant. These properties are conferred by the selection of the macromer components as well as addition of various groups to the components.
• the term "polymerizable" means that the regions have the capacity to form additional covalent bonds resulting in macromer interlinking, for example, carbon-carbon double bonds of acrylate-type molecules. Such polymerization is characteristically initiated by free-radical formation resulting from photon absorption of certain dyes and chemical compounds to ultimately produce free-radicals, although it can be obtained using other methods and reagents known to those skilled in the art.
• the polymeric materials must be biocompatible, i.e., not eliciting a significant or unacceptable toxic or immunogenic response following administration to or implantation into an individual.
• polymeric materials which are biocompatible, including both natural and synthetic polymers.
• examples include proteins (of the same origin as the recipient), polysaccharides such as chondroitin sulfate and hyaluronic acid, polyurethanes, polyesters, polyamides, and acrylates.
• Polymers can be degradable or non-degradable.
• polymeric materials will be selected based on a combination of properties conferred by the various components, which may include a water soluble regions such as PEG or PVA, biodegradable regions such as regions that degrade hydrolytically, and groups that can be used to polymerize the macromers in situ.
• a water soluble regions such as PEG or PVA
• biodegradable regions such as regions that degrade hydrolytically
• groups that can be used to polymerize the macromers in situ may include a water soluble regions such as PEG or PVA, biodegradable regions such as regions that degrade hydrolytically, and groups that can be used to polymerize the macromers in situ.
• Water-Soluble and/or Tissue Adhesive Regions There are a variety of water soluble materials that can be incorporated into the polymers.
• the term "at least substantially water soluble" is indicative that the solubility should be at least about 5 g/100 ml of aqueous solution.
• the core water soluble region can consist of poly(ethylene glycol), poly(ethylene oxide), poly(vinyl acetate), poly(vinyl alcohol), poly(vinylpyrrolidone), poly(ethyloxazoline), poly(ethylene oxide)-co-poly(propyleneoxide) block copolymers, polysaccharides or carbohydrates such as hyaluronic acid, dextran, heparan sulfate, chondroitin sulfate, heparin, or alginate, or proteins such as gelatin, collagen, albumin, or ovalbumin.
• polysaccharides or carbohydrates such as hyaluronic acid, dextran, heparan sulfate, chondroitin sulfate, heparin, or alginate
• proteins such as gelatin, collagen, albumin, or ovalbumin.
• Hydrophilic regions will generally be tissue adhesive. Both hydrophobic and hydrophilic polymer including large number of exposed carboxylic groups will be tissue or bioadhesive. Ligands such as RGD peptides and lectins which bind to carbohydrate molecules on cells can also be bound to the polymer to increase tissue adhesiveness. Degradable Regions
• Polyesters (Holland et al., 1986 Controlled Release, 4:155-180) of ⁇ - hydroxy acids (viz., lactic acid, glycolic acid), are the most widely used biodegradable materials for applications ranging from closure devices (sutures and staples) to drug delivery systems (U.S. Patent No. 4,741,337 to Smith et al. ; Spilizewski et al. , 1985 J Control. Rel. 2: 197-203).
• poly(hydroxy acids) In addition to the poly(hydroxy acids), several other polymers are known to biodegrade, including polyanhydrides and polyorthoesters, which take advantage of labile backbone linkages, as reported by Domb et al., 1989 Macromolecules, 22:3200; Heller et al, 1990 Biodegradable Polymers as Drug Delivery Systems, Chasin, M. and Langer, R., Eds., Dekker, New York, 121-161. Polyaminoacids have also been synthesized since it is desirable to have polymers that degrade into naturally occurring materials, as reported by Miyake et al, 1974, for in vivo use.
• the time required for a polymer to degrade can be tailored by selecting appropriate monomers. Differences in crystallinity also alter degradation rates. Due to the relatively hydrophobic nature of these polymers, actual mass loss only begins when the oligomeric fragments are small enough to be water soluble. Hence, initial polymer molecular weight influences the degradation rate.
• the biodegradable region is preferably hydrolyzable under in vivo conditions. Hydrolyzable groups may be polymers and oligomers of glycolide, lactide, ⁇ -caprolactone, other ⁇ -hydroxy acids, and other biologically degradable polymers that yield materials that are non-toxic or present as normal metabolites in the body.
• Preferred poly( ⁇ -hydroxy acid)s are poly(glycolic acid), poly(DL-lactic acid) and poly(L-lactic acid).
• Other useful materials include poly(amino acids), poly(anhydrides), poly(orthoesters), and poly(phosphoesters).
• Polylactones such as poly( ⁇ - caprolactone), poly( ⁇ -caprolactone), poly( ⁇ -valerolactone) and poly(gamma- butyrolactone), for example, are also useful.
• Biodegradable regions can also be constructed from polymers or monomers using linkages susceptible to biodegradation by enzymes, such as ester, peptide, anhydride, orthoester, and phosphoester bonds.
• Degradable materials of biological origin are well known, for example, crosslinked gelatin.
• Hyaluronic acid has been crosslinked and used as a degradable swelling polymer for biomedical applications (U.S. Patent No. 4,987,744 to della Valle et al., U.S. Patent 4,957,744 to Delia Valle et al. (1991) Polym. Mater. Sci. Eng. , 62:731 -735]).
• Biodegradable Hydrogels A number of polymers have been described which include both water soluble regions and biodegradable regions. Sawhney et al., (1990) J. Biomed. Mater. Res. 24:1397-1411, copolymerized lactide, glycolide and ⁇ - caprolactone with PEG to increase its hydrophilicity and degradation rate.
• the polymerizable regions are separated by at least one degradable region to facilitate uniform degradation in vivo.
• the polymerizable regions can be attached directly to degradable extensions or indirectly via water soluble nondegradable sections so long as the polymerizable regions are separated by a degradable section.
• the macromer composition contains a simple water soluble region coupled to a degradable region
• one polymerizable region may be attached to the water soluble region and the other attached to the degradable extension or region.
• the water soluble region forms the central core of the macromer composition and has at least two degradable regions attached to the core.
• At least two polymerizable regions are attached to the degradable regions so that, upon degradation, the polymerizable regions, particularly in the polymerized gel form, are separated.
• the central core of the macromer composition is formed by a degradable region, at least two water soluble regions can be attached to the core and polymerizable regions attached to each water soluble region. The net result will be the same after gel formation and exposure to in vivo degradation conditions.
• the macromer composition has a water soluble backbone region and a degradable region affixed to the macromer backbone. At least two polymerizable regions are attached to the degradable regions, so that they are separated upon degradation, resulting in gel product dissolution.
• the macromer backbone is formed of a nondegradable backbone having water soluble regions as branches or grafts attached to the degradable backbone. Two or more polymerizable regions are attached to the water soluble branches or grafts.
• the backbone may be star shaped, which may include a water soluble region, a biodegradable region or a water soluble region which is also biodegradable.
• the star region contains either water soluble or biodegradable branches or grafts with polymerizable regions attached thereto. Again, the polymerizable regions must be separated at some point by a degradable region. Polymerizable groups.
• the polymerizable regions are preferably polymerizable by photoinitiation by free radical generation, most preferably in the visible or long wavelength ultraviolet radiation.
• the preferred polymerizable regions are acrylates, diacrylates, oligoacrylates, dimethacrylates, oligomethoacrylates, or other biologically acceptable photopolymerizable groups.
• a preferred tertiary amine is triethanol amine.
• Useful photoinitiators are those which can be used to initiate by free radical generation polymerization of the macromers without cytotoxicity and within a short time frame, minutes at most and most preferably seconds.
• Preferred dyes as initiators of choice for LWUV initiation are ethyl eosin, 2,2-dimethoxy-2-phenyl acetophenone, other acetophenone derivatives, and camphorquinone.
• crosslinking and polymerization are initiated among copolymers by a light-activated free-radical polymerization initiator such as 2,2-dimethoxy-2-phenylacetophenone or a combination of ethyl eosin (lO ⁇ -lO "2 milliM) and triethanolamine (0.001 to 0.1 M), for example.
• a light-activated free-radical polymerization initiator such as 2,2-dimethoxy-2-phenylacetophenone or a combination of ethyl eosin (lO ⁇ -lO "2 milliM) and triethanolamine (0.001 to 0.1 M), for example.
• the choice of the photoinitiator is largely dependent on the photopolymerizable regions.
• the macromer includes at least one carbon-carbon double bond
• light absorption by the dye causes the dye to assume a triplet state, the triplet state subsequently reacting with the amine to form a free radical which initiates polymerization.
• Preferred dyes for use with these materials include eosin dye and initiators such as 2,2- dimethyl-2-phenylacetophenone, 2-methoxy-2-phenylacetophenone, and camphorquinone.
• copolymers may be polymerized in situ by long wavelength ultraviolet light or by laser light of about 514 nm, for example.
• Initiation of polymerization is accomplished by irradiation with light at a wavelength of between about 200-700 nm, most preferably in the long wavelength ultraviolet range or visible range, 320 nm or higher, most preferably about 514 nm or 365 nm.
• photooxidizable and photoreducible dyes that may be used to initiate polymerization. These include acridine dyes, for example, acriblarine; thiazine dyes, for example, thionine; xanthine dyes, for example, rose bengal; and phenazine dyes, for example, methylene blue. These are used with cocatalysts such as amines, for example, triethanolamine; sulphur compounds, for example, RSO 2 R' ; heterocycles, for example, imidazole; enolates; organometallics; and other compounds, such as N-phenyl glycine. Other initiators include camphorquinones and acetophenone derivatives.
• Thermal polymerization initiator systems may also be used. Such systems that are unstable at 37°C and would initiate free radical polymerization at physiological temperatures include, for example, potassium persulfate, with or without tetramethyl ethylenediamine; benzoylperoxide, with or without triethanolamine; and ammonium persulfate with sodium bisulfite.
• initiation chemistries may be used besides photoinitiation. These include, for example, water and amine initiation schemes with isocyanate or isothiocyanate containing macromers used as the polymerizable regions.
• the polymeric materials are a biodegradable, polymerizable and at least substantially water soluble macromer composition.
• the first macromer includes at least one water soluble region, at least one NO carrying region and at least one free radical- polymerizable region.
• the second macromer includes at least one water soluble region and at least two free radical polymerizable regions. The regions can, in some embodiments, be both water soluble and biodegradable.
• the macromer composition is polymerized by exposure of the polymerizable regions to free radicals generated, for example, by photosensitive chemicals and dyes.
• Examples of these macromers are PVA or PEG-oligoglycolyl- acrylates.
• end caps permits rapid polymerization and gelation.
• Acrylates are preferred because they can be polymerized using several initiating systems, e.g., an eosin dye, by brief exposure to ultraviolet or visible light.
• a poly(ethyleneglycol) or PEG central structural unit (core) is preferred on the basis of its high hydrophilicity and water solubility, accompanied by excellent biocompatibility.
• a short oligo or poly( ⁇ - hydroxy acid), such as polyglycolic acid, is selected as a preferred chain extension because it rapidly degrades by hydrolysis of the ester linkage into glycolic acid, a harmless metabolite.
• polyglycolic acid Although highly crystalline polyglycolic acid is insoluble in water and most common organic solvents, the entire macromer composition is water-soluble and can be rapidly gelled into a biodegradable network while in contact with aqueous tissue fluids.
• Such networks can be used to entrap and homogeneously disperse water- soluble drugs and enzymes and to deliver them at a controlled rate. Further, they may be used to entrap particulate suspensions of water-insoluble drugs.
• Other preferred chain extensions are polylactic acid, polycaprolactone, polyorthoesters, and polyanhydrides. Polypeptides may also be used.
• Such "polymeric" blocks should be understood to include timeric, trimeric, and oligomeric blocks.
• PVA contains many pendant hydroxyl groups.
• PVA polyvinyl alcohol
• the macromers disclosed in U.S. Patent No. 5,508,317 are PVA prepolymers modified with pendant crosslinkable groups, such as acrylamide groups containing crosslinkable olefinically unsaturated groups. These macromers can be polymerized by photopolymerization or redox free radical polymerization, for example.
• the starting polymers are, in particular, derivatives of polyvinyl alcohol or copolymers of vinyl alcohol that contain, for example, a 1,3-diol skeleton.
• the crosslinkable group or the further modifier can be bonded to the starting polymer skeleton in various ways, for example through a certain percentage of the 1,3-diol units being modified to give a 1,3-dioxane, which contains a crosslinkable radical, or a further modifier in the 2-position.
• Another possibility is for a certain percentage of hydroxyl groups in the starting polymer to be esterified by means of an unsaturated organic acid, these ester-bonded radicals containing a crosslinkable group.
• the hydrophobicity of these macromers can be increased by substituting some of the pendant hydroxyl groups with more hydrophobic substituents.
• the properties of the macromers, such as hydrophobicity can also be modified by incorporating a comonomer in the macromer backbone.
• the macromers can also be formed having pendant groups crosslinkable by other means.
• L-arginine is a NO donor, since L-arginine is a substrate for NO synthase, and thus administration of L-arginine increases endogenous NO production and elicits responses similar to those caused by NO donors in most cases.
• NO donors include molsidomine, CAS754, SPM-5185, and SIN-1.
• Other compounds capable of producing and/or donating NO may also be used. These include organic nitrates, nitrosylating, compounds, nitrosoesters, and L-arginine.
• the molecules which produce NO, or release or generate NO are preferably attached to regions containing nucleophiles and/or thiols such as S-nitrosothiols capable of forming a complex with NO.
• the polymeric materials can also be used for drug delivery, preferably localized release of prophylactic, therapeutic or diagnostic agents at the site where the materials are needed, although the polymeric materials can be loaded with agent to be released systemically.
• agents include proteins or peptides, polysaccharides, nucleic acid molecules, and simple organic molecules, both natural and synthetic.
• Representative materials include antibiotics, antivirals, and antifungal drugs, anti-inflammatories (steroidal or non-steroidal), hormones, growth factors, cytokines, neuroactive agents, vasoconstrictors and other molecules involved in the cardiovascular responses, enzymes, antineoplastic agents, local anesthetics, antiangiogenic agents, antibodies, drugs affecting reproductive organs, and oligonucleotides such as antisense oligonucleotides. Diagnostic materials may be radioactive, bound to or cleave a chromogenic substrate, or detectable by ultrasound, x- ray, mri, or other standard imaging means.
• agents can be mixed with macromer prior to polymerization, applied into or onto the polymer, or bound to the macromer prior to or at the time of polymerization, either covalently or ionically, so that the agent is released by degradation (enzymatic or hydrolytic) or diffusion at the site where the polymer is applied.
• Polymeric materials capable of releasing physiological amounts of NO for prolonged periods of time can be applied to sites on or in a patient in need of treatment thereof.
• Representative disorders or conditions that can be treated with NO include restenosis, thrombosis, asthma, wound healing, arthritis, and penile or female erectile dysfunction.
• the material is typically applied as a macromer solution and polymerized in situ, although polymerization can be initiated prior to application.
• Wound Healing The formulations are particularly useful for treatment of wounds, such as ulcers and burns. ... all types of wounds, including burns, surgical wounds, and open leg and foot wounds.
• ulcers There are generally three types of open leg wounds, termed ulcers: venous stasis ulcers, generally seen in sedentary elderly people when blood flow to the leg becomes sluggish; decubitus ulcers, also termed pressure sores or bed sores, which occurs most often in people who are bedridden and are unable to frequently change position; and diabetic foot ulcers, caused by poor blood circulation to the feet. Due to the aging of the population, there will likely be a greater demand for effective and user friendly wound treatments in the near future.
• wound refers to all types of tissue injuries, including those inflicted by surgery and trauma, including burns, as well as injuries from chronic or acute medical conditions, such as atherosclerosis or diabetes.
• a preferred application is a method of reducing the effects of restenosis on post-surgical patients.
• the method includes coating the surface within an artery with an aqueous solution of light-sensitive free radical polymerizable initiator and a number of macromers.
• the coated artery is subjected to a Xenon arc laser inducing polymerization of the macromers.
• the physiological conditions within the artery will induce the release of NO. This release will be strictly localized for prolonged periods of time.
• Prevention of Surgical Adhesions is a method of reducing the effects of restenosis on post-surgical patients.
• a preferred application is a method of reducing formation of adhesions after a surgical procedure in a patient.
• the method includes coating damaged tissue surfaces in a patient with an aqueous solution of a light-sensitive free-radical polymerization initiator and a macromer solution as described above.
• the coated tissue surfaces are exposed to light sufficient to polymerize the macromer.
• the light-sensitive free-radical polymerization initiator may be a single compound (e.g., 2,2- dimethoxy-2-phenyl acetophenone) or a combination of a dye and a cocatalyst (e.g., ethyl eosin and triethanol amine).
• Tissue Adhesives may be a single compound (e.g., 2,2- dimethoxy-2-phenyl acetophenone) or a combination of a dye and a cocatalyst (e.g., ethyl eosin and triethanol amine).
• the macromer is mixed with a photoinitiator or photoinitiator/cocatalyst mixture to form an aqueous mixture and the mixture is applied to a tissue surface to which tissue adhesion is desired.
• the tissue surface is contacted with the tissue with which adhesion is desired, forming a tissue junction.
• the tissue junction is then irradiated until the macromers are polymerized. Tissue Coatings.
• an ultrathin coating is applied to the surface of a tissue, most preferably the lumen of a tissue such as a blood vessel.
• a tissue most preferably the lumen of a tissue such as a blood vessel.
• An initiator is applied to the surface of the tissue, allowed to react, adsorb or bond to tissue, the unbound initiator is removed by dilution or rinsing, and the macromer solution is applied and polymerized. This method is capable of creating uniform polymeric coating of between one and 500 microns in thickness, most preferably about twenty microns, which does not evoke thrombosis or localized inflammation.
• the polymeric materials can also be used to create tissue supports by forming shaped articles within the body to serve a mechanical function.
• Such supports include, for example, sealants for bleeding organs, sealants for bone defects and space-fillers for vascular aneurisms. Further, such supports can include strictures to hold organs, vessels or tubes in a particular position for a controlled period of time.
• the polymeric materials can be use as carriers for biologically active materials such as therapeutic, prophylactic or diagnostic agents, including hormones, enzymes, antibiotics, antineoplastic agents, and cell suspensions.
• the polymeric material may be used to temporarily preserve functional properties of an agent to be released, as well as provide prolonged, controlled release of the agent into local tissues or systemic circulation.
• the macromers are polymerized with the biologically active materials to form microspheres or nanoparticles containing the biologically active material.
• the macromer, photoinitiator, and agent to be encapsulated are mixed in an aqueous mixture. Particles of the mixture are formed using standard techniques, for example, by mixing in oil to form an emulsion, forming droplets in oil using a nozzle, or forming droplets in air using a nozzle.
• the suspension or droplets are irradiated with a light suitable for photopolymerization of the macromer.
• These materials are particularly useful for controlled drug delivery of hydrophilic materials, since the water soluble regions of the polymer enable access of water to the materials entrapped within the polymer. Moreover, it is possible to polymerize the macromer composition containing the material to be entrapped without exposing the material to organic solvents. Release may occur by diffusion of the material from the polymer prior to degradation and/or by diffusion of the material from the polymer as it degrades, depending upon the characteristic pore sizes within the polymer, which is controlled by the molecular weight between crosslinks and the crosslink density. Deactivation of the entrapped material is reduced due to the immobilizing and protective effect of the gel and catastrophic burst effects associated with other controlled-release systems are avoided.
• the enzyme can be exposed to substrate while the enzyme is entrapped, provided the gel proportions are chosen to allow the substrate to permeate the gel. Degradation of the polymer facilitates eventual controlled release of free macromolecules in vivo by gradual hydrolysis of the terminal ester linkages.
• examples 1-3 three classes of NO-producing, PEG-based polymers have been synthesized and their NO release rate constants determined in vitro under physiological conditions.
• the biological response to appropriate materials has been evaluated in vitro using cultured smooth muscle cells and endothelial cells and in vivo using a rat carotid artery injury model that resembles restenosis in man.
• the materials include
• BAB block copolymers of polyethylene glycol (A) with polycysteine (B) that are subsequently reacted with NaNO to form S-nitrosothiols BAB block copolymers of polyethylene glycol (“PEG”) (A) and diethylenetriamine (“DETA”) (B) that are subsequently reacted with NO gas to form nucleophile/NO complexes
• BAB block copolymers of polyethylene glycol (A) and polylysine (B) that are subsequently reacted with NO gas to form nucleophile/NO complexes. All polymers are further terminated with reactive acrylate groups to allow rapid photopolymerization in situ.
• Such materials would be expected to have good biocompatibility, provided that a water soluble, biocompatible polymer such as PEG comprises the bulk of the material and has a sufficiently high molecular weight, and to slowly biodegrade due to the presence of two ester bonds and two amide bonds in each polymer chain.
• a water soluble, biocompatible polymer such as PEG comprises the bulk of the material and has a sufficiently high molecular weight, and to slowly biodegrade due to the presence of two ester bonds and two amide bonds in each polymer chain.
• PEG polyethylene glycol
• PVA hydrogels As demonstrated by examples 4 and 5, three types of PVA hydrogels were made and demonstrated release of NO and incorporated drug (bFGF): PVA-NH 2 -NO hydrogels; PVA-Cys-NO hydrogels; PVA-NO-bFGF hydrogels. The results are similar to those for the PEG based hydrogels.
• an acryloyl-PEG-CYSNO polymer was formed by first reacting polyethylene glycol N-hydroxysuccinimide monoacrylate (ACRL-PEG-NHS, MW 3400, commercially available from Shearwater Polymers, Huntington, AL) with L-cysteine at an 1 :2 molar ratio in 50 mM sodium bicarbonate buffer (pH 8.5) for 2 hours; the product was then dialyzed in a cellulose ester membrane (Molecular weight cutoff 500, Spectrum Labs, Websites, Website, CA) in diH 2 O, and lyophilized.
• ACRL-PEG-NHS polyethylene glycol N-hydroxysuccinimide monoacrylate
• acryloyl-PEG-Cys copolymer was performed using gel permeation chromatography (GPC) with an evaporative light scattering detector and a UV detector at 260 nm (Polymer Laboratories, Amherst, MA). Successful synthesis of acryloyl-PEG-Cys was determined by a shift in the position of the peak from the evaporative light scattering detector. The copolymer was then reacted with an equimolar amount of NaNO at pH 2 and 37°C for 20 minutes to form S-nitrosocysteine. Conversion of thiol groups to S- nitrosothiols was measured using the Ellman's assay (Hermanson, 1995).
• the acryloyl-PEG-CYSNO polymer was incorporated into photopolymerizable hydrogels by mixing with PEG-diacrylate (MW 3400) at a 1 :10 molar ratio in aqueous solution with 1500 ppm 2,2-dimethoxy-2-phenyl acetophenone as a long wavelength ultraviolet initiator. 0.15% N-vinylpyrrolidone was present in this mixture as it was used as a solvent for the photoinitiator. Exposure to UV light (365 nm, 10 mW/cm 2 ) was used to crosslink the polymer, resulting in conversion to a hydrogel (Sawhney et al., 1993). Production of NO by the hydrogels was quantified using the Griess assay.
• Example 2 Synthesis of PEG-Lys Macromers.
• Example 3 Synthesis of DETA-NO-nucleophile complex hydrogels.
• Poly(vinyl alcohol) (Hoechst, Mowiol 4-88) was dissolved in diH 2 0 and warmed to 95°C in a round bottom flask under continuous stirring. After one hour, the solution was cooled to room temperature, and a crosslinkable acetal group, methacrylamidoacetaldehyde dimethyl acetal (NAAADA) was added. The amine acetal, gamma-aminobutyraldehyde diethyl acetal, was also added, and the mixture was acidified using glacial acetic acid and 37% hydrochloric acid. The mixture was allowed to stir at room temperature for nine hours, after which the pH was adjusted to pH 3.6 using triethylamine.
• NAAADA methacrylamidoacetaldehyde dimethyl acetal
• the solution was then diafiltered through a MW 3000 cellulose membrane against diH 2 O at 6.5 times the volume of polymer solution.
• the polymer concentration was adjusted to 22% w/v using diafiltration, and the pH was adjusted to 7.4 with IN NaOH.
• the amine concentration of the polymer was determined using the ninhydrin assay.
• the neutralized amine-modified polymer was placed in a round bottom flask with stopcock. The flask was evacuated and filled with nitric oxide gas until the desired conversion of amines to NO nucleophile complexes was achieved.
• Photocrosslinked hydrogels were formed from the PVA-NH -NO by adding 0.1% Irgacure 2959 (Ciba-Geigy) photoinitiator (based on total solution volume) and then exposing to UV light (2 mW/cm 2 , 365 nm) for 30 seconds. Addition of the photoinitiator brings the final polymer concentration to 20% w/v.
• Irgacure 2959 Ciba-Geigy photoinitiator
• PVA-NH 2 was synthesized as described above. The amine terminus of cysteine was acetylated using acetic anhydride, and the carboxyl end of the cysteine was coupled to the PVA-NH 2 using water-soluble ED AC chemistry. The resulting PVA-Cys was then purified using diafiltration and brought to a concentration of 22% w/v. PVA-Cys-NO was formed by adding sodium nitrite at an equimolar amount to cysteine residues, adjusting the pH to 2, and incubating at 37°C for 15 minutes. The extent of reaction of cysteine to Cys-NO was assayed using both the Ellman's and Griess reactions.
• PVA-NO-bFGF hydrogels For PVA-NO-bFGF hydrogels, the above procedure was used to make the PVA-NO polymer. Immediately prior to exposure to UV light, 25 ⁇ g/ml bFGF was added to the polymer solution and mixed well. Gels were crosslinked as described earlier and stored in HEPES buffered saline, pH 7.4, 37°C. Release of bFGF was quantified using the BCA assay (Pierce Chemicals), and NO release was assayed using the Griess reaction.
• Example 7 NO-release Rates from acryloyl-PEG-Lyss-NO hydrogels Following preparation and photopolymerization of the NO-releasing materials as described above, the hydrogels were weighed and stored in HEPES buffered saline, pH 7.4, at 37°C. Aliquots of the buffer were removed at each time point and replaced with fresh buffer. The samples from each time point were then analyzed for nitrite content using a colorimetric assay based on the Griess reaction.
• NO release from acryloyl-PEG-Lys 5 -NO hydrogels is shown in Figure 4.
• NO release from acryloyl -PEG-DETA-NO hydrogels is shown in
• Example 8 NO-release Rates from PVA-NO-bFGF hydrogels The release of NO release from PVA-NO-bFGF hydrogels was determined in the same manner as Example 7 and is shown in Figure 7.
• Figures 12a and 12b respectively, show the temporal release of NO and a growth factor, bFGF, over time from PVA-NO-bFGF hydrogels. Release of NO continues for well over 12 hours, while the growth factor is completely released within the first 5 hours.
• bFGF a growth factor
• Example 9 Effects of NO-releasing Macromers on Cultured Smooth Muscle Cells: Proliferation and Viability
• cultured smooth muscle cells were grown in the presence of NO-releasing materials, and the effects of those materials on the cells evaluated.
• Smooth muscle cells isolated from Wistar-Kyoto rats (passage 11-15, provided by T. Scott- Burden) were cultured in Minimum Essential Medium supplemented with 10% FBS, 2 mM L-glutamine, 500 units penicillin, and 100 mg/L streptomycin, at 37°C in a 5% CO 2 environment. The cells were seeded into
• NO- nucleophile complexes (Lys-NO and DETA-NO) were formed by reacting either L-lysine or DETA with NO gas in water for 24 hours.
• Soluble Cys- NO was synthesized by reacting an equimolar amount of L-cysteine with NaNO 2 at pH 2 and 37°C for 20 minutes. All NO donor solutions were adjusted to pH 7.4 prior to addition to cell cultures.
• hydrogels were removed and the blood was then incubated with the collagen-coated glass slides (two per group) for 20 minutes at 37°C and then rinsed with HBS. Platelet counts per field of view at 40x were counted under a fluorescent microscope (Zeiss Axiovert 135, Thornwood, NY) in four randomly chosen areas per slide. Photos of platelets which had been exposed to control PEG-diacrylate or acryloyl-PEG-CYSNO hydrogels demonstrate that exposure to the NO- releasing hydrogels inhibits platelet adhesion to thrombogenic surfaces. Glass slides coated with collagen were used as a thrombogenic surface to which platelets would normally adhere.

Landscapes

• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Macromonomer-Based Addition Polymer (AREA)
• Materials For Medical Uses (AREA)
• Medicinal Preparation (AREA)
• Colloid Chemistry (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=22541347

Family Applications (1)

Country Status (7)

Families Citing this family (19)

Citations (1)

Family Cites Families (3)

• 2000
  • 2000-09-01 WO PCT/US2000/024058 patent/WO2001015738A2/en not_active Application Discontinuation
  • 2000-09-01 CZ CZ20011899A patent/CZ20011899A3/cs unknown
  • 2000-09-01 AU AU71016/00A patent/AU7101600A/en not_active Abandoned
  • 2000-09-01 CA CA002353531A patent/CA2353531A1/en not_active Abandoned
  • 2000-09-01 EP EP00959750A patent/EP1194171A2/de not_active Withdrawn
  • 2000-09-01 MX MXPA01005338A patent/MXPA01005338A/es unknown
  • 2000-09-01 IL IL14330500A patent/IL143305A0/xx unknown

Patent Citations (1)

Also Published As

Similar Documents

Legal Events